| Literature DB >> 26690179 |
Megumi Yamagishi1, Ritsuko Hosoda-Yabe2,3, Hideki Tamai4,2, Miku Konishi4,2, Akihiro Imamura5, Hideharu Ishida6, Tomio Yabe7, Hiromune Ando8,9, Makoto Kiso4,2.
Abstract
LLG-3 is aEntities:
Keywords: MAPK/ERK signaling; PC12 cell; SH-SY5Y cell; ganglioside; neurite outgrowth; starfish; structure-activity relationship
Mesh:
Substances:
Year: 2015 PMID: 26690179 PMCID: PMC4699235 DOI: 10.3390/md13127062
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of ganglioside LLG-3 and its analogues synthesized in this study.
Scheme 1Synthesis of LLG-3 tetrasaccharide 2. Reagents and conditions: (a) i. H2, Pd(OH)2-C/EtOAc, RT; ii. LiCl/Pyr, reflux; iii. 0.1 M NaOH aq., RT to 40 °C, 49% (3 steps).
Scheme 2Synthesis of demethylated LLG-3 tetrasaccharide 3. Reagents and conditions: (a) i. H2, Pd(OH)2-C, EtOAc, RT; ii. Bz2O, DMAP/Pyr, RT, 94% (2 steps); (b) i. CAN, toluene/MeCN/H2O (5/6/3), 0 °C; ii. Bz2O, DMAP/Pyr, RT; iii. NH2NH2·AcOH/DMF, RT, 52% (3 steps); (c) CCl3CN, DBU/CH2Cl2, 0 °C, 81%; (d) H2, Pd(OH)2-C/EtOAc, RT, 97%; (e) i. LiCl/Pyr, reflux; ii. 0.1 M NaOH aq., RT, 80% (2 steps). DMAP = 4-dimethylaminopyridine, CAN = cerium(IV) ammonium nitrate, DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene.
Scheme 3Synthesis of LLG-3 trisaccharide 4. (a) Zn, AcOH/MeCN, RT, 92%; (b) NH2NH2·AcOH/THF, RT, 99%; (c) i. H2, Pd(OH)2-C/EtOAc, RT; ii. LiCl/Pyr, reflux; iii. 0.1 M NaOH aq., RT, 79% (3 steps). NIS = N-iodosuccinimide, TESOTf = triethylsilyl trifluoromethanesulfonate, EDC = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, HOBt = 1-hydroxybenzotriazole.
Scheme 4Synthesis of LLG-3 disaccharide 5. (a) Zn, AcOH/MeCN, RT, 90%; (b) NH2NH2·AcOH/THF, RT, 99%; (c) i. LiCl/Pyr, reflux; ii. 0.1 M NaOH aq., RT, 78% (2 steps).
Scheme 5Synthesis of LLG-3 monosaccharide 6. (a) CAc2O, DMAP/THF, RT, quant.; (b) NH2NH2·AcOH/THF, RT, 80%; (c) i. LiCl/Pyr, reflux; ii. 0.1 M NaOH aq., RT, 48% (2 steps). CAc = chloroacetyl, IPA = isopropenyl acetate, Ts = p-toluenesulfonyl, SCP = 1-selenocarbamoylpiperidine, TTBP = 2,4,6-tri-tert-butylpyrimidine.
Figure 2Neurite outgrowth evaluation in PC12 cells. Rat PC12 cells with a low serum culture medium containing 5 ng/mL of NGF were incubated with ganglioside 1 (A); tetrasaccharide 2 (B); tetrasaccharide 3 (C); trisaccharide 4 (D); disaccharide 5 (E) and monosaccharide 6 (F) for neurite outgrowth evaluation. The error bar represents the standard deviation (S.D.). * p < 0.05 with Dunnett’s test compared with the 0 nM group.
Figure 3Trisaccharide 4-induced neurite outgrowth in SH-SY5Y cells. Neuroblastoma SH-SY5Y cells were incubated with trisaccharide 4 for 3 days in medium containing 1% FBS and the mean total neurite length per cell calculated from 90 cells was measured at each dose. Trisaccharide 4 stimulated neurite extensions of SH-SY5Y cells in a dose-dependent manner. The error bar represents the standard deviation (S.D.). * p < 0.05 with Dunnett’s test compared with the 0 nM group.
Figure 4Effect of trisaccharide 4 on phosphorylation of p44/42 MAPK (ERK 1/2) and Akt. SH-SY5Y cells were incubated with trisaccharide 4 (1 or 10 nM) or 40 ng/mL of NGF for 5 to 60 min (A,C); or with 0 to 100 nM of trisaccharide 4 for 5 min (B) after pre-incubation with serum-free medium for 1 h. Cell lysates (3 µg of total protein in each lane) were separated by SDS-PAGE. The expression levels of ERK, p-ERK, Akt, and p-Akt were quantified by densitometric analysis of western blot and results were expressed as the ratio of phosphorylated forms (p-ERK or p-Akt) to non-phosphorylated forms (ERK or Akt). Trisaccharide 4 evoked rapid, dose-dependent phosphorylation of ERK 1/2 to an extent similar to that of NGF (A,B); although 4 showed no effect on Akt phosphorylation (C). The graphs are expressed as the mean ± S.D. from five (A,C) or six (B) independent experiments. * p < 0.05 with Dunnett’s test compared with the 0 min group (A,C) or the 0 nM group (B).
Figure 5Effects of MEK inhibitor U0126 on neurite extension and ERK 1/2 phosphorylation. SH-SY5Y cells were incubated with trisaccharide 4 (A) 0 nM; (B–E) 1 nM and U0126 (A, B) 0 µM; (C) 0.5 µM; (D) 1 µM; (E) 5 µM for 3 days in medium containing 1% FBS. Mean total neurite length per cell of 180 cells was measured at each dose (F). Statistical significances were determined by Dunnett’s test compared with U0126 0 µM within each trisaccharide 4-treated group (0 or 1 nM group) (* p < 0.05) and by t-test (0 vs. 1 nM at each U0126 dose level) (††† p < 0.001, †† p < 0.01, and † p < 0.05).
Figure 6Effects of MEK inhibitor U0126 on neurite extension and ERK 1/2 phosphorylation. (A) SH-SY5Y cells were incubated with trisaccharide 4 (0 or 1 nM) for 5 min after pre-incubation with serum-free medium containing U0126 for 1 h, and cell lysates were analyzed as described in Figure 4 (n = 5). The error bar represents the standard deviation (S.D.). Statistical significances were determined by Dunnett’s test compared with U0126 0 µM within each trisaccharide 4-treated group (0 or 1 nM group) (** p < 0.01 and * p < 0.05) and by t-test (0 vs. 1 nM at each U0126 dose level) († p < 0.05); (B) ERK 1/2 phosphorylation was investigated by Phos-tag SDS-PAGE.